Mithra to Hold Presentations on Key Role of Estrogens in Women’s Health, Including Estetrol (E4), at FIGO World Congress
October 10 2023 - 12:00PM
Mithra to Hold Presentations on Key Role of Estrogens in Women’s
Health, Including Estetrol (E4), at FIGO World Congress
- Mithra to hold joint symposium with
partner Gedeon Richter on 11 October
- Four leading experts will outline why
estrogens are critical in contraception and postmenopausal
symptoms
- Data show promising safety and
efficacy features of E4, key ingredient in
ESTELLE® and DONESTA®
Liege, Belgium, 10 October 2023 – 18:00
CEST – Mithra (Euronext Brussels: MITRA), a company
dedicated to Women’s Health, will hold four presentations on the
role of estrogens - including its Estetrol (E4) - in a symposium at
the International Federation of Gynecology and Obstetrics (FIGO)
World Congress, which will take place 9-12 October in Paris.
The 11 October symposium, which Mithra is
holding jointly with its partner Gedeon Richter Plc., will
highlight why estrogens are critical in contraception and for
postmenopausal women. Estrogen plays an important role across
organs and tissues and is pivotal in governing the female
reproductive system and secondary sex characteristics. It is at the
heart of women’s health, due to its intricate role, and regulation
of multiple functions.
E4 is a key active pharmaceutical ingredient in
both Mithra’s first E4-based combined oral contraceptive (COC)
ESTELLE®, which is already marketed, and its next generation
hormone therapy candidate for postmenopausal symptoms, DONESTA®.
Robust data from preclinical and clinical studies underscoring E4's
compelling safety and efficacy profile.
Dr. Graham Dixon, Chief Scientific
Officer of Mithra, said: “The symposium at the FIGO
congress will provide an opportunity to present the vital role of
estrogen in women’s health, and the potential groundbreaking
characteristics of our E4 product to support healthcare
professionals and women’s confidence in hormone therapy. While
ongoing research promises deeper understanding, current data
strongly suggests that E4's unique molecular mode of action and
metabolism contribute notably to its selective pharmacological
profile, suggesting its favorable benefit–risk ratio in
transforming women's health. In particular, the exclusive and
innovative profile of E4 shows its possible ability to
significantly improve contraception and treatment of postmenopausal
women, with a strong safety profile. We are grateful to our
presenters, who are all leading experts in the field, and look
forward to this opportunity to discuss the role of estrogens with
the scientific community at FIGO.”
Pre-clinical and clinical data have shown its
proapoptotic effect on breast cancer tissue, indicating therapeutic
promise. In postmenopausal patients with breast cancer, E4 shows
objective antitumor effects, promising a valuable addition to
breast cancer interventions. As a component in a COC with
drospirenone and under development for menopausal hormone therapy,
E4 demonstrates therapeutic efficacy beyond contraception. It
elicits estrogenic activity in uterovaginal tissues, contributing
to bone turnover, and shows positive effects on cardiovascular
functions. E4's profile shows a low estrogenic impact on the liver
and hemostasis balance, suggesting a diminished thrombotic
risk.
Details of the presentations at the FIGO World
Congress are as follows:
-
Exploring how estrogens are essential for a woman’s health,
throughout her life
Presenter:
Professor Mitchell Creinin, USA
Time:
13:00-13:15 CET
-
Discovering the exclusive and innovative profile of
E4
Presenter:
Professor Jean-Michel Foidart, Belgium
Time:
13:15-13:30 CET
-
Highlighting an effective contraceptive, with neutral liver
and kidney impact
Presenter:
Professor Mitchell Creinin, USA
Time:
13:30-13:45 CET
-
Discussing how we can meet expectations in
menopause
Presenter:
Professor Amanda Black, Canada
Time:
13:45-14:05 CET
For more information, please
contact:
Mithra Pharmaceuticals SAAlex Sokolowski, PhDHead
of Investor Relationsinvestorrelations@mithra.com+32 (0)4 349 28
22 |
Frédérique DepraetereCommunication Directorinfo@mithra.com +32 (0)4
349 28
22 |
Chris MaggosCohesion Bureauchris.maggos@cohesionbureau.com+41 79
367 6254 |
|
|
|
About Mithra
Mithra Pharmaceuticals SA (Euronext: MITRA) is a
Belgian biopharmaceutical company dedicated to transforming Women’s
Health by offering new choices through innovation, with a
particular focus on contraception and menopause. Mithra’s goal is
to develop products offering better efficacy, safety and
convenience, meeting women’s needs throughout their life span.
Mithra explores the potential of the unique native estrogen
estetrol in a wide range of applications in women health and
beyond. After having successfully launched the first estetrol-based
product in 2021, the contraceptive pill ESTELLE®, Mithra is now
focusing on its second product DONESTA®, the next-generation
hormone therapy. Mithra also offers partners a complete spectrum of
solutions from early drug development, clinical batches and
commercial manufacturing of complex polymeric products (vaginal
ring, implants) and complex liquid injectables and biologicals
(vials, pre-filled syringes or cartridges) at its technological
platform Mithra CDMO. Active in more than 100 countries around the
world, is headquartered in Liège, Belgium. www.mithra.com
ESTELLE® and DONESTA® are registered trademarks
of Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
Subscribe to our mailing list on investors.mithra.com to receive
our press releases by email or follow us on our social media
:Linkedin • X • Facebook |
- French MDN_2023-10-11_Mithra FIGO_FR (002)
- English MDN_2023-10-11_Mithra FIGO_EN Correction
Mithra Pharmaceuticals (TG:1TM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Mithra Pharmaceuticals (TG:1TM)
Historical Stock Chart
From Dec 2023 to Dec 2024